To advance the academic development of laboratory medicine, respond to the national call to support and develop the domestic healthcare industry, and implement the requirements outlined in the National Action Plan to Contain Bacterial Resistance (2016–2020) and the General Office of the National Health and Family Planning Commission’s Notice on Further Strengthening Clinical Management of Antimicrobial Use to Curb Bacterial Resistance, this training workshop—aimed at exploring the antibiotic resistance profiles of common clinical pathogens in China and developing antibiotic‑use strategies tailored to the country’s specific circumstances—was held on October 14, 2017, at the DoubleTree by Hilton Beijing. The event was hosted by the Beijing Branch of the Chinese Medical Association and co‑organized by Dier Biotechnology.

This training workshop brought together representatives from 17 hospitals in Beijing, Tianjin, and Hebei. Liu Xiang, Secretary-General of the Beijing Branch of the Chinese Medical Association, delivered the opening address and extended his best wishes for the successful conclusion of the event. Professor Xu Yingchun, Director of the Department of Laboratory Medicine at Peking Union Medical College Hospital and Head of the Quality Management Center of the National Bacterial Resistance Surveillance Network, chaired the session, sharing with the participants China’s national policies on bacterial resistance testing, the progress of related initiatives, and future directions for development. He also offered recommendations and expressed expectations regarding the advancement and refinement of automated systems for bacterial identification and antimicrobial susceptibility testing.

Following the opening ceremony, Secretary-General Liu Xiang, Professor Xu Yingchun, along with Mr. Lu Yanjun, Director of Key Accounts at Dier Biotech, and Mr. Chen Yunwei, Director of Marketing and Services, jointly unveiled the DL-96A—the first domestically produced fully automated bacterial identification and antimicrobial susceptibility testing system.

As the spectrum of infecting pathogens and bacterial resistance patterns evolve, developing automated in vitro antimicrobial susceptibility testing systems that align with China’s national antimicrobial resistance surveillance efforts is critical for enhancing both hospital workflow efficiency and the quality of resistance‑testing services. Zhang Peng, Manager of the Marketing Department at Dier Biotech, provided a detailed overview of the DL‑96A bacterial identification and susceptibility analysis system. This product integrates automated incubation, automated detection, expert‑guided prompts, and automatic report generation, while also incorporating expanded drug‑concentration gradients for susceptibility testing and optimized drug selection. It fully complies with CLSI 2016 and CARSS guidelines, thereby filling a gap in the market for automated bacterial identification and susceptibility analysis solutions that comprehensively meet the needs of Chinese hospitals.

This training session featured presentations and discussions by Professor Zhang Ge from Peking Union Medical College Hospital, Professor Zhou Yu from the General Hospital of the People’s Liberation Army, Professor Song Jianmei from Chaoyang Hospital, and Professor Li Guojiang from Fangshan First Hospital, who respectively addressed “An Introduction to TGC Tigecycline and PB Polymyxin Susceptibility Testing,” “An Overview of Antimicrobial Susceptibility Testing within the CARSS Resistance Surveillance Network,” “Clinical Applications of Group B Streptococcus Screening,” and “CARSS‑Required Testing for PIP (Piperacillin), AMS (Amikacin), AMS (Ampicillin–Sulbactam), and GEN (Gentamicin).” The conference fostered a rich academic atmosphere. Representatives from attending hospitals engaged in in-depth exchanges and discussions on topics such as tigecycline susceptibility testing and the interpretation of susceptibility criteria, culminating in a successful conclusion.